DU Guanhua
Principal Investigator
Education background:
10/1978-07/1982: Shandong Medical University, Pharmacy, B.S. degree
09/1986-07/1989: Tongji Medical University, Pharmacology, M.S. degree
09/1992-07/1995: Institute of Materia Medica, CAMS & PUMC, Pharmacology, Ph.D. degree
Work experience:
07/1982-08/1986: Shandong Binzhou Medical College, Department of Pharmacology Research, Assistant
09/1986-08/1992: Shandong Binzhou Medical College, Department of Traditional Chinese medicine Research, Vice director/Lecturer
09/1995-05/1998: University of Liege, Belgium, Post-doctor
06/1998-Present: Institutes of Materia Medica, CAMS & PUMC, National Center for Pharmaceutical Screening, Professor/Director
Du Guanhua is mainly engaged in drug discovery and development. His research focuses on drug screening methods and theory, drug effect and mechanism in the areas of cerebrovascular and neuropharmacology. In recent years, he has presided over and completed more than 20 items of national scientific research projects. His research work has made good progress in high throughput drug screening, drug targets identification, drug mechanism study, virtual drug screening, bioinformatics research and the traditional Chinese medicine study. Based on these achievements, Du has won 20 science and technology prizes and the honor of "national outstanding scientific research worker". He has published hundreds of research papers. He is the editor-in-chief of "Pharmacological Research – Modern Chinese Medicine", and the associate editor of "Pharmacology & Therapeutics" and "Acta Pharmacologica Sinica". He was appointed as an Academician of the International Eurasian Academy of Sciences in 2019.
1. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2020, 395(10236):1569-1578.
2. The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro. Biochemical Pharmacology, 2021, 183: 114302.
3. The strategies and techniques of drug discovery from natural products. Pharmacology & Therapeutics, 2020, 107686.
4. Bexarotene combined with lapatinib for the treatment of Cushing's disease: evidence based on drug repositioning and experimental confirmation. Signal Transduction and Targeted Therapy, 2020, 5(1): 175.
5. Ethno-medicinal study of Artemisia ordosica Krasch. (traditional Chinese/Mongolian medicine) extracts for the treatment of allergic rhinitis and nasosinusitis. Journal of Ethnopharmacology, 2020, 248: 112262.
6. Ganoderic acid A protects neural cells against NO stress injury in vitro via stimulating β adrenergic receptors. Acta Pharmacologica Sinica, 2020, 41(4): 516-522.
7. Baicalein attenuates caspase-independent cells death via inhibiting PARP-1 activation and AIF nuclear translocation in cerebral ischemia/reperfusion rats. Apoptosis, 2020, 25: 354-369.
8. miR-182-3p/Myadm contribute to pulmonary artery hypertension vascular remodeling via a KLF4/p21-dependent mechanism. Theranostics, 2020, 10(12):5581-5599.
9. Total flavonoids from Anchusa italica Retz. improve cardiac function and attenuate cardiac remodeling post myocardial infarction in mice. Journal of Ethnopharmacology, 2020, 257: 112887.
10. Salvianolic acid D alleviates cerebral ischemia-reperfusion injury by suppressing the cytoplasmic translocation and release of HMGB1-triggered NF-κB activation to inhibit inflammatory response. Mediators of Inflammation, 2020, 2020:9049614.
11. MELK is an oncogenic kinase essential for metastasis, mitotic progression, and programmed death in lung carcinoma. Signal Transduction and Targeted Therapy, 2020, 5(1): 279.
12. Comprehensive lipidome profiling of the kidney in early-stage diabetic nephropathy. Frontiers in Endocrinology, 2020, 11: 359.
13. Baicalein administered in the subacute phase ameliorates ischemia-reperfusion-induced brain injury by reducing neuroinflammation and neuronal damage. Biomed Pharmacother. 2019, 117: 109102.
14. Inhibition of FOXO3a/BIM signaling pathway contributes to the protective effect of salvianolic acid A against cerebral ischemia/reperfusion injury. Acta Pharm Sin B, 2019, 9(3): 505-515.
15. The Sphingosine Kinase-1/Sphingosine-1-Phosphate Axis in Cancer: Potential Target for Anticancer Therapy. Pharmacol Ther. 2019,195:85-89.
1. Pharmacological Advances in Natural Product Drug Discovery. Academic Press , 2020, ISBN: 978-0-12-820185-5.
2. Natural Small Molecule Drugs from Plants. Springer , 2019, ISBN: 978-7-117-29101-9.
1. The second award, National Science and Technology Progress Award. -2019.
2. The second award, National Science and Technology Progress Award. -2016.
3. The second award, Chinese Medical Science and Technology Award. -2019.
4. The third award, Chinese Medical Science and Technology Award. -2017.
5. The third award, Chinese Medical Science and Technology Award. -2014.
6. The third award, Chinese Medical Science and Technology Award. -2011.
7. The second award, Science and Technology Progress Award of Ministry of Education. -2018.
8. The second award, Science and Technology Progress Award of Ministry of Education. -2013.
9. The first award, Beijing Science and Technology Award. -2014.
10. The third award, Beijing Science and Technology Award. -2014.
11. The second award, Beijing Science and Technology Award. -2011.
12. The second award, Beijing Science and Technology Award. -2011.
13. The second award, Beijing Science and Technology Award. -2008.
14. The second award, Beijing Science and Technology Award. -2002.
